Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer＇s Disease  

作　　者：Xiaoli Pan Zhichun Chen Guoqiang Fei Shumei Pan Weiqi Bao Shuhua Ren Yihui Guan Chunjiu Zhong Xiaoli Pan;Zhichun Chen;Guoqiang Fei;Shumei Pan;Weiqi Bao;Shuhua Ren;Yihui Guan;Chunjiu Zhong(Department of Neurology, Zhongshan Hospital, State Key Laboratory of Medical Neurobiology, Institutes of Brain Science and Collaborative Innovation Center for Brain Science, Fudan University, Shanghai 200032, China;PET Center, Huashan Hospital, Fudan University,Shanghai 200443, China)

机构地区：[1]Department of Neurology, Zhongshan Hospital, State Key Laboratory of Medical Neurobiology, Institutes of Brain Science and Collaborative Innovation Center for Brain Science, Fudan University, Shanghai 200032, China [2]PET Center, Huashan Hospital, Fudan University,Shanghai 200443, China

出　　处：《Neuroscience Bulletin》2016年第6期591-596,共6页神经科学通报（英文版）

基　　金：supported by the Key Fund for Developing New Drugs from the Ministry of Science and Technology of China(2014ZX09101005-005);the National Natural Science Foundation of China(81071019);the National Key Basic Research Program of China(2011CBA00400);the Natural Science Foundation of Shanghai Municipality,China(13JC1401500);the Fund for Medical Emerging Cutting-Edge Technology in Shanghai of China (SHDC12012114)

摘　　要：Abstract To date, we still lack disease-modifying thera- pies for Alzheimer＇s disease （AD）. Here, we report that long-term administration of benfotiamine improved the cognitive ability of patients with AD. Five patients with mild to moderate AD received oral benfotiamine （300 mg daily） over 18 months. All patients were examined by positron emission tomography with Pittsburgh compound B （PiB-PET） and exhibited positive imaging with β- amyloid deposition, and three received PiB-PET imaging at follow-up. The five patients exhibited cognitive improve- ment as assayed by the Mini-Mental Status Examination （MMSE） with an average increase of 3.2 points at month 18 of benfotiamine administration. The three patients who received follow-up PiB-PET had a 36.7% increase in the average standardized uptake value ratio in the brain com- pared with that in the first scan. Importantly, the MMSE scores of these three had an average increase of 3 points during the same period. Benfotiamine significantly improved the cognitive abilities of mild to moderate AD patients independently of brain amyloid accumulation. Ourstudy provides new insight to the development of disease- modifying therapy.To date, we still lack disease-modifying thera- pies for Alzheimer＇s disease （AD）. Here, we report that long-term administration of benfotiamine improved the cognitive ability of patients with AD. Five patients with mild to moderate AD received oral benfotiamine （300 mg daily） over 18 months. All patients were examined by positron emission tomography with Pittsburgh compound B （PiB-PET） and exhibited positive imaging with β- amyloid deposition, and three received PiB-PET imaging at follow-up. The five patients exhibited cognitive improve- ment as assayed by the Mini-Mental Status Examination （MMSE） with an average increase of 3.2 points at month 18 of benfotiamine administration. The three patients who received follow-up PiB-PET had a 36.7% increase in the average standardized uptake value ratio in the brain com- pared with that in the first scan. Importantly, the MMSE scores of these three had an average increase of 3 points during the same period. Benfotiamine significantly improved the cognitive abilities of mild to moderate AD patients independently of brain amyloid accumulation. Ourstudy provides new insight to the development of disease- modifying therapy.

关 键 词：Alzheimer＇s disease. Therapy. Benfotiamine PiB-PET Amyloid deposition 

分 类 号：R749.16[医药卫生—神经病学与精神病学]